In a report released yesterday, Vamil Divan from Credit Suisse maintained a Buy rating on Merck & Company (MRK), with a price target of $86. The company’s shares closed yesterday at $79.01, close to its 52-week high of $80.19.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -3.2% and a 42.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merck & Company with a $83.14 average price target.
See today’s analyst top recommended stocks >>
Based on Merck & Company’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $10.86 billion and net profit of $1.95 billion. In comparison, last year the company earned revenue of $10.31 billion and had a GAAP net loss of $56 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
